Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 5;6(2):52.
doi: 10.3390/neurosci6020052.

Natural Compounds That Target Glioma Stem Cells

Affiliations
Review

Natural Compounds That Target Glioma Stem Cells

Mariia Yaroshenko et al. NeuroSci. .

Abstract

Gliomas are the most common central nervous system tumors and account for 30% of all primary brain tumors, 80% of all malignant ones, and the vast majority of deaths that are caused by brain tumors. Among them, glioblastoma multiforme has the most aggressive and invasive course. Due to its heterogeneity, it is difficult to treat, and one of the reasons for this are glioma stem cells (GSCs). Therapies such as radiotherapy and chemotherapy are used to treat gliomas but do not bring the expected results. Therefore, treatments targeting glioma stem cells are emerging. A promising strategy is to target GSCs with natural compounds. This review aims to describe the problem of glioma stem cells, the treatment of gliomas, and therapies based on natural compounds, which are promising for the future.

Keywords: glioblastoma; glioma stem cells; glioma treatment; natural compounds.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Differences between proneuronal (blue) and mesenchymal (green) glioma stem cells (GSCs).
Figure 2
Figure 2
Mechanism of anticancer activity of naturally derived compounds against GSCs.

Similar articles

References

    1. Molinaro A.M., Taylor J.W., Wiencke J.K., Wrensch M.R. Genetic and molecular epidemiology of adult diffuse glioma. Nat. Rev. Neurol. 2019;15:405–417. doi: 10.1038/s41582-019-0220-2. - DOI - PMC - PubMed
    1. Schaff L.R., Mellinghoff I.K. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329:574–587. doi: 10.1001/jama.2023.0023. - DOI - PMC - PubMed
    1. D’Alessio A., Proietti G., Sica G., Scicchitano B.M. Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue. Cancers. 2019;11:469. doi: 10.3390/cancers11040469. - DOI - PMC - PubMed
    1. Angom R.S., Nakka N.M.R., Bhattacharya S. Advances in Glioblastoma Therapy: An Update on Current Approaches. Brain Sci. 2023;13:1536. doi: 10.3390/brainsci13111536. - DOI - PMC - PubMed
    1. Wu W., Klockow J.L., Zhang M., Lafortune F., Chang E., Jin L., Wu Y., Daldrup-Link H.E. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol. Res. 2021;171:105780. doi: 10.1016/j.phrs.2021.105780. - DOI - PMC - PubMed

LinkOut - more resources